From
Dr. Alberto Tozzi
Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Oct 2026 · 1 min read
In brief
In brief
This study evaluates the safety and efficacy of etanercept, a TNF inhibitor, in 25 children with juvenile idiopathic arthritis who began treatment before age 4. The research addresses a critical knowledge gap in biologic therapy for very young patients with JIA, examining both adverse events and clinical response measures.
Written by the GCMD Library team from the article.
To evaluate safety, tolerability, and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis (JIA) under 4 years of age. Data were collected at every visit during treatment with etanercept in 25 children who began treatment at a mean age of 3 years (range 18-48 months). Safety endpoints included the incidence of any adverse events. Efficacy endpoints included the America…
Educational content from recorded physician discussions — not medical advice. Talk to your (or your child's) care team about your situation.
Article
A cohort study of a tailored web intervention for preconception care.
Alberto Tozzi · Published Oct 2026
Article
[Obesity and cardiovascular risk in children].
Alberto Tozzi · Published Oct 2026
Podcast
Le funzioni e gli usi dell'intelligenza artificiale per la salute
Alberto Tozzi · 14 min · Published Oct 2026
Podcast
Data to impact: connecting the future of European pediatrics with Alberto Tozzi
Alberto Tozzi · 20 min · Published Oct 2026
Article
Towards learning healthcare systems in Italy: opportunities and challenges of AI at point-of-care.
Alberto Tozzi · Published Oct 2026
Article
Methicillin-resistant Staphylococcus aureus nasal colonization in a department of pediatrics: a cross-sectional study.
Alberto Tozzi · Published Oct 2026